TY - JOUR
T1 - Tumor Staging of Endocervical Adenocarcinoma
T2 - Recommendations from the International Society of Gynecological Pathologists
AU - Park, Kay J.
AU - Roma, Andres
AU - Singh, Naveena
AU - Gilks, C. Blake
AU - Oliva, Esther
AU - Abu-Rustum, Nadeem
AU - Ramirez, Pedro T.
AU - McCluggage, W. Glenn
N1 - Funding Information:
This study was funded in part through the NIH/NCI Support Grant P30 CA008748 for Memorial Sloan Kettering Cancer Center.
Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - The International Federation of Gynecology and Obstetrics (FIGO) updated its staging system for cervical cancer in 2018 with changes that affect size criteria for early stage disease, as well as including pathology and radiology in addition to clinical assessment to be used in staging. Lymph node involvement was also included in the staging system. In early stage disease, pathologic findings are crucial in determining stage, which in turn determine treatment and prognosis for the patient. Therefore, it is imperative that there are unified and consistent methods and recommendations for assessing and reporting pathologic parameters for accurate staging. We describe the changes in the revised FIGO staging scheme and discuss controversial issues in cervical cancer staging from a pathologic perspective. We also provide practical recommendations regarding these parameters based on literature review and/or expert opinion/consensus.
AB - The International Federation of Gynecology and Obstetrics (FIGO) updated its staging system for cervical cancer in 2018 with changes that affect size criteria for early stage disease, as well as including pathology and radiology in addition to clinical assessment to be used in staging. Lymph node involvement was also included in the staging system. In early stage disease, pathologic findings are crucial in determining stage, which in turn determine treatment and prognosis for the patient. Therefore, it is imperative that there are unified and consistent methods and recommendations for assessing and reporting pathologic parameters for accurate staging. We describe the changes in the revised FIGO staging scheme and discuss controversial issues in cervical cancer staging from a pathologic perspective. We also provide practical recommendations regarding these parameters based on literature review and/or expert opinion/consensus.
UR - http://www.scopus.com/inward/record.url?scp=85101468796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101468796&partnerID=8YFLogxK
U2 - 10.1097/PGP.0000000000000758
DO - 10.1097/PGP.0000000000000758
M3 - Article
C2 - 33570866
AN - SCOPUS:85101468796
SN - 0277-1691
VL - 40
SP - S92-S101
JO - International Journal of Gynecological Pathology
JF - International Journal of Gynecological Pathology
ER -